Cyclerion Therapeutics (CYCN) News Today → The Overlooked Retirement Asset You Probably Don’t Own (From Crypto 101 Media) (Ad) Free CYCN Stock Alerts $2.85 0.00 (0.00%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 8, 2024 | investorplace.comCYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q1 2024April 28, 2024 | benzinga.comSage Therapeutics Stock (NASDAQ:SAGE), Quotes and News SummaryApril 21, 2024 | morningstar.comCyclerion Therapeutics Inc Ordinary Shares CYCNApril 5, 2024 | investorplace.comCYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q4 2023April 4, 2024 | marketbeat.comTrading was temporarily halted for "CYCN" at 01:04 PM with a stated reason of "LULD pause."March 6, 2024 | investing.comCyclerion Therapeutics Inc (CYCN)February 29, 2024 | uk.finance.yahoo.comCyclerion Therapeutics, Inc. (CYCN)February 26, 2024 | marketbeat.comTrading was temporarily halted for "CYCN" at 09:02 AM with a stated reason of "LULD pause."February 23, 2024 | benzinga.comCyclerion Therapeutics Stock (NASDAQ:CYCN) Dividends: History, Yield and DatesDecember 20, 2023 | marketbeat.comTrading was temporarily halted for "CYCN" at 09:12 AM with a stated reason of "LULD pause."December 19, 2023 | marketbeat.comTrading was temporarily halted for "CYCN" at 10:12 AM with a stated reason of "LULD pause."December 4, 2023 | msn.comCyclerion Therapeutics appoints Graul as PresidentNovember 30, 2023 | finance.yahoo.comCyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge InnovatorNovember 28, 2023 | finance.yahoo.comCyclerion Therapeutics' Market Cap Drops To US$5.0m Leaving Insiders With LossesJuly 31, 2023 | finance.yahoo.comTisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion AssetsJune 30, 2023 | ca.finance.yahoo.comCYCN - Cyclerion Therapeutics, Inc.June 2, 2023 | finanznachrichten.deCyclerion Therapeutics, Inc.: Cyclerion Regains Compliance with Nasdaq Minimum Bid Price RequirementJune 1, 2023 | msn.comCyclerion Therapeutics in compliance with Nasdaq minimum bid price ruleMay 16, 2023 | marketbeat.comTrading was temporarily halted for "CYCN" at 02:05 PM with a stated reason of "LULD pause."May 16, 2023 | marketbeat.comTrading was temporarily halted for "CYCN" at 02:05 PM with a stated reason of "LULD pause."May 16, 2023 | marketbeat.comTrading was temporarily halted for "CYCN" at 12:05 PM with a stated reason of "LULD pause."May 16, 2023 | marketbeat.comTrading was temporarily halted for "CYCN" at 12:05 PM with a stated reason of "LULD pause."May 16, 2023 | finanznachrichten.deCyclerion Therapeutics, Inc.: Cyclerion Announces Reverse Stock SplitMay 15, 2023 | msn.comCyclerion announces 1 for 20 reverse stock splitMay 12, 2023 | finance.yahoo.comCyclerion Therapeutics to Sell Assets for $81M, CEO Transition To New Spin-Off Private Company Established By Shareholders, New InvestorsMay 12, 2023 | finanznachrichten.deCyclerion Therapeutics, Inc.: Cyclerion Announces Corporate Updates and Q1 2023 Financial ResultsMay 12, 2023 | msn.comCyclerion Therapeutics down 6% on spin off agreementMay 11, 2023 | finance.yahoo.comCyclerion Announces Corporate Updates and Q1 2023 Financial ResultsMay 11, 2023 | finance.yahoo.comCyclerion Announces Definitive Agreement for Zagociguat and CY3018April 3, 2023 | finanznachrichten.deCyclerion Therapeutics, Inc.: Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment AgreementMarch 27, 2023 | marketwatch.comCyclerion Gets FDA Orphan Designation for Zagociguat in Mitochondrial Diseases >CYCNMarch 23, 2023 | finanznachrichten.deCyclerion Therapeutics, Inc.: Cyclerion Reports Corporate Update and Full Year 2022 Financial ResultsMarch 22, 2023 | finance.yahoo.comCyclerion Reports Corporate Update and Full Year 2022 Financial ResultsNovember 23, 2022 | msn.comWhy American Eagle Outfitters Shares Climbed Over 18%; Here Are 78 Biggest Movers From YesterdayNovember 22, 2022 | marketwatch.comCyclerion Shares Rise After Spurned Bid for AssetsNovember 22, 2022 | markets.businessinsider.comCyclerion Rejects Unsolicited Proposal To Buy Its AssetsNovember 22, 2022 | finance.yahoo.comCyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The CompanyOctober 7, 2022 | finance.yahoo.comCyclerion Therapeutics lays off nearly half of workforceSeptember 9, 2022 | reuters.comCyclerion Therapeutics IncAugust 9, 2022 | finance.yahoo.comCyclerion Therapeutics, Inc. (CYCN) Reports Q2 Loss, Misses Revenue EstimatesAugust 9, 2022 | finance.yahoo.comCyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial ResultsAugust 8, 2022 | finance.yahoo.comIs Cyclerion Therapeutics (NASDAQ:CYCN) In A Good Position To Invest In Growth?July 28, 2022 | msn.comRecap Of Thursday's Biotech Catalysts - End of The Day SummaryJuly 28, 2022 | finance.yahoo.comCyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)June 17, 2022 | finance.yahoo.comCyclerion Neurology Candidate Shows Encouraging Action In Preclinical StudiesJune 10, 2022 | marketwatch.comCyclerion Therapeutics Posts Positive Study Data for MELAS TreatmentMay 11, 2022 | finance.yahoo.comAs Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) drops to US$26m market cap, insiders might rethink their US$2.7m stock purchase earlier this yearMay 4, 2022 | seekingalpha.comCyclerion Therapeutics reports Q1 resultsMay 4, 2022 | finance.yahoo.comCyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial ResultsMarch 23, 2022 | marketbeat.comCyclerion Therapeutics (NASDAQ:CYCN) Upgraded at Zacks Investment ResearchZacks Investment Research raised shares of Cyclerion Therapeutics from a "sell" rating to a "hold" rating in a research note on Wednesday. Get Cyclerion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCN and its competitors with MarketBeat's FREE daily newsletter. Email Address Breaking News: Elon Musk Invents New Type of A.I. (Shocking) (Ad)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone. Click here for the full story… CYCN Media Mentions By Week CYCN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CYCN News Sentiment▼1.890.50▲Average Medical News Sentiment CYCN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CYCN Articles This Week▼00▲CYCN Articles Average Week Get Cyclerion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: VCNX News Today EFTR News Today BNOX News Today HEPA News Today VIRI News Today UPC News Today KTTA News Today CVKD News Today TRVN News Today CANF News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CYCN) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersObama’s Forever Term [exposed]Porter & Company4 Cryptos BETTER than BitcoinTrue Market InsidersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingElon’s New Device is About to Shock the WorldInvestorPlaceMissed NVDA? Buy this AI stock NOWChaikin AnalyticsProtect Your Bank Account Before It’s Too LateWeiss RatingsUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclerion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.